{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:07:42Z","timestamp":1794506862839,"version":"4.9.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      To report the outcomes and safety of 100\n                      <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>\n                      g\/0.1 cc intravitreal topotecan (IVitT100) as monotherapy for refractory\/recurrent intraocular retinoblastoma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective single-center study of 7 patients with retinoblastoma who received IVitT100 as monotherapy between January 2024 and December 2024 with a minimum follow-up of 3 months after the last injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>At presentation, six eyes were classified as Group D and one as Group C, according to the International Classification of Retinoblastoma. High-dose topotecan was administered for refractory and recurrent disease in 2 (29%) and 5 (71%) eyes, respectively. The active disease was in the form of a intraretinal tumor with vitreous seeds (n = 3, 43%), intraretinal tumor with epiretinal seeds (n = 1, 14%), isolated intraretinal tumor (n = 1, 14%), isolated subretinal seeds (n = 1, 14%), or isolated vitreous seeds (n = 1, 14%). At a mean follow-up of 7 months (median, 6 months; range, 3\u201310) from the last injection of IVitT00, tumor control was achieved in 100% (4 of 4) eyes with vitreous seeds, 100% (1 of 1) with epiretinal seeds, 100% (1 of 1) with subretinal seeds, and 60% (3 of 5) with retinal tumor. Overall, tumor control was achieved in 5 eyes (71%) with IVitT100 monotherapy. Additional treatments were warranted in two eyes for complete tumor control. Globe salvage was achieved in all eyes (100%). The electroretinogram (n = 4) showed no significant changes compared with the baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>IVitT100 is a safe option for refractory or recurrent intraocular retinoblastoma and holds promise for controlling refractory vitreous seeds, subretinal seeds, and intraretinal tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004601","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T21:00:09Z","timestamp":1752094809000},"page":"2142-2149","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["HIGH-DOSE INTRAVITREAL TOPOTECAN (100 \u00b5G\/0.1 CC) AS MONOTHERAPY FOR RECURRENT\/REFRACTORY INTRAOCULAR RETINOBLASTOMA IN SEVEN EYES"],"prefix":"10.1097","volume":"45","author":[{"given":"Vijitha S.","family":"Vempuluru","sequence":"first","affiliation":[{"name":"The Operation Eyesight Universal Institute for Eye Cancer, Hyderabad, India; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Raval","sequence":"additional","affiliation":[{"name":"The Operation Eyesight Universal Institute for Eye Cancer, Hyderabad, India; and"},{"name":"Anant Bajaj Retina Institute, LV Prasad Eye Institute, Hyderabad, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-9961","authenticated-orcid":false,"given":"Swathi","family":"Kaliki","sequence":"additional","affiliation":[{"name":"The Operation Eyesight Universal Institute for Eye Cancer, Hyderabad, India; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251021","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ajo.2014.07.025","article-title":"Retinoblastoma. Fifty years of progress. The LXXI edward jackson memorial lecture","volume":"158","author":"Grossniklaus","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R2-20251021","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/bjophthalmol-2011-301450","article-title":"Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications","volume":"96","author":"Munier","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R3-20251021","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archophthalmol.2012.1983","article-title":"Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma","volume":"130","author":"Ghassemi","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R4-20251021","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamaoncol.2019.6716","article-title":"Global retinoblastoma presentation and analysis by national income level","volume":"6","author":"Fabian","year":"2020","journal-title":"JAMA Oncol"},{"key":"R5-20251021","doi-asserted-by":"crossref","first-page":"1084e1087","DOI":"10.1136\/bjophthalmol-2011-301016","article-title":"Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilization of the needle track","volume":"96","author":"Munier","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R6-20251021","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jamaophthalmol.2017.4600","article-title":"Risk of extraocular extension in eyes with retinoblastoma receiving intravitreous chemotherapy","volume":"135","author":"Francis","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R7-20251021","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/APO.0000000000000322","article-title":"Chemotherapy for retinoblastoma: impact of intravitreal chemotherapy","volume":"10","author":"Raval","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R8-20251021","first-page":"S2468","article-title":"Intravitreal melphalan versus topotecan for vitreous seeds in retinoblastoma: a comparative study of 64 asian Indian eyes","volume":"19","author":"Agarwal","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R9-20251021","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/bjophthalmol-2020-318529","article-title":"Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study","volume":"106","author":"Bogan","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R10-20251021","doi-asserted-by":"crossref","first-page":"109026","DOI":"10.1016\/j.exer.2022.109026","article-title":"Ocular and systemic toxicity of high-dose intravitreal topotecan in rabbits: implications for retinoblastoma treatment","volume":"218","author":"Del Sole","year":"2022","journal-title":"Exp Eye Res"},{"key":"R11-20251021","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.3928\/01913913-20230110-01","article-title":"Intravitreal topotecan 90 \u00b5g for recurrent solid retinoblastoma tumors is effective and not toxic","volume":"60","author":"Abramson","year":"2023","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R12-20251021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000004283","article-title":"High-dose intravitreal topotecan for recurrent retinoblastoma, subretinal seeds, and vitreous seeds","volume":"45","author":"Shields","year":"2025","journal-title":"Retina"},{"key":"R13-20251021","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12886-019-1059-4","article-title":"Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients","volume":"19","author":"Xue","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"R14-20251021","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ophtha.2016.12.015","article-title":"Efficacy and toxicity of Intravitreous chemotherapy for retinoblastoma: four-year experience","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"key":"R15-20251021","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.ophtha.2006.06.018","article-title":"The International Classification of Retinoblastoma predicts chemoreduction success","volume":"113","author":"Shields","year":"2006","journal-title":"Ophthalmology"},{"key":"R17-20251021","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/13816810.2014.973045","article-title":"Classification and management of seeds in retinoblastoma. Ellsworth lecture ghent august 24th 2013","volume":"35","author":"Munier","year":"2014","journal-title":"Ophthalmic Genet"},{"key":"R18-20251021","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1080\/13816810.2022.2141801","article-title":"Retinal and optic nerve relapse in retinoblastoma secondary to epiretinal and epipapillary vitreous seeds implantation documented by optical coherence tomography","volume":"43","author":"Stathopoulos","year":"2022","journal-title":"Ophthalmic Genet"},{"key":"R19-20251021","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.4103\/IJO.IJO_2722_23","article-title":"Electroretinographic changes in the inner and outer retinal layers before and after intravenous chemotherapy for retinoblastoma","volume":"72","author":"Kannan","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"R20-20251021","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamaophthalmol.2014.414","article-title":"Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma","volume":"132","author":"Ghassemi","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R21-20251021","doi-asserted-by":"crossref","first-page":"490e495","DOI":"10.1136\/bjophthalmol-2017-310641","article-title":"Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma","volume":"102","author":"Rao","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R22-20251021","doi-asserted-by":"crossref","first-page":"1215e1224","DOI":"10.1016\/j.ophtha.2024.04.022","article-title":"Intravitreal topotecan for vitreous seeds in retinoblastoma: a long-term review of 91 eyes","volume":"131","author":"Sen","year":"2024","journal-title":"Ophthalmology"},{"key":"R23-20251021","first-page":"1124","article-title":"The photopic negative response of the macaque electroretinogram: reduction by experimental glaucoma","volume":"40","author":"Viswanathan","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R25-20251021","doi-asserted-by":"crossref","first-page":"397e400","DOI":"10.1080\/13816810.2020.1776336","article-title":"Optimizing the storage of chemotherapeutics for ophthalmic oncology: stability of topotecan solution for intravitreal injection","volume":"41","author":"Bossacoma","year":"2020","journal-title":"Ophthalmic Genet"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T19:00:43Z","timestamp":1761073243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004601","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}